Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
4.09
USD
|
+3.54%
|
|
+3.02%
|
-14.79%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
93.33
|
4,079
|
10,817
|
883.9
|
570.2
|
572.4
|
-
|
-
|
Enterprise Value (EV)
1 |
335.1
|
3,836
|
9,756
|
-228.1
|
169.7
|
62
|
90.14
|
572.4
|
P/E ratio
|
-0.72
x
|
-15.3
x
|
-6.1
x
|
-1.22
x
|
-0.89
x
|
-5.66
x
|
-103
x
|
-18.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5
x
|
8.58
x
|
9.44
x
|
0.45
x
|
0.58
x
|
0.68
x
|
0.58
x
|
0.59
x
|
EV / Revenue
|
18
x
|
8.07
x
|
8.51
x
|
-0.12
x
|
0.17
x
|
0.07
x
|
0.09
x
|
0.59
x
|
EV / EBITDA
|
-
|
-
|
-
|
0.37
x
|
-0.32
x
|
-0.56
x
|
-0.44
x
|
-
|
EV / FCF
|
-2.42
x
|
-39.5
x
|
36.8
x
|
0.45
x
|
-0.22
x
|
-0.91
x
|
-0.3
x
|
1.56
x
|
FCF Yield
|
-41.3%
|
-2.53%
|
2.72%
|
221%
|
-452%
|
-110%
|
-331%
|
64.3%
|
Price to Book
|
-0.69
x
|
12.6
x
|
-30.9
x
|
-1.38
x
|
-0.93
x
|
-0.78
x
|
-0.94
x
|
-
|
Nbr of stocks (in thousands)
|
23,449
|
36,578
|
75,608
|
85,979
|
118,790
|
139,953
|
-
|
-
|
Reference price
2 |
3.980
|
111.5
|
143.1
|
10.28
|
4.800
|
4.090
|
4.090
|
4.090
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
18.66
|
475.6
|
1,146
|
1,982
|
983.7
|
845.5
|
986.4
|
971.6
|
EBITDA
1 |
-
|
-
|
-
|
-615.7
|
-525.3
|
-111.5
|
-206.8
|
-
|
EBIT
1 |
-129.6
|
-416.7
|
-1,687
|
-644.7
|
-566.5
|
-92.51
|
-37.38
|
-40.75
|
Operating Margin
|
-694.44%
|
-87.62%
|
-147.13%
|
-32.53%
|
-57.59%
|
-10.94%
|
-3.79%
|
-4.19%
|
Earnings before Tax (EBT)
1 |
-132.7
|
-418.3
|
-1,715
|
-653.6
|
-543
|
-125.2
|
-82.86
|
-45.5
|
Net income
1 |
-132.7
|
-418.3
|
-1,744
|
-657.9
|
-545.1
|
-112.3
|
-90.66
|
-40.85
|
Net margin
|
-711.04%
|
-87.94%
|
-152.12%
|
-33.2%
|
-55.41%
|
-13.28%
|
-9.19%
|
-4.2%
|
EPS
2 |
-5.510
|
-7.270
|
-23.44
|
-8.420
|
-5.410
|
-0.7230
|
-0.0396
|
-0.2250
|
Free Cash Flow
1 |
-138.5
|
-97.16
|
265.5
|
-505
|
-767.7
|
-68.5
|
-298
|
368
|
FCF margin
|
-742.04%
|
-20.43%
|
23.16%
|
-25.48%
|
-78.05%
|
-8.1%
|
-30.21%
|
37.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
178.8
|
222.2
|
704
|
185.9
|
734.6
|
357.4
|
80.95
|
424.4
|
187
|
291.3
|
101.4
|
76.65
|
77.42
|
616.6
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-118.8
|
-
|
-
|
-
|
-
|
-172.8
|
-149
|
-121
|
-109
|
186
|
EBIT
1 |
-307.1
|
-825
|
209.3
|
-483
|
-127.2
|
-243.9
|
-312.8
|
55.46
|
-125.6
|
-183.6
|
-137.4
|
-112.8
|
-112
|
259.8
|
Operating Margin
|
-171.74%
|
-371.27%
|
29.73%
|
-259.76%
|
-17.31%
|
-68.24%
|
-386.37%
|
13.07%
|
-67.19%
|
-63.01%
|
-135.49%
|
-147.13%
|
-144.72%
|
42.14%
|
Earnings before Tax (EBT)
1 |
-316.4
|
-829.7
|
206.1
|
-509.1
|
-166.1
|
-184.5
|
-292.7
|
57.86
|
-131.5
|
-176.7
|
-141
|
-115.7
|
-112.5
|
244
|
Net income
1 |
-322.4
|
-846.3
|
203.4
|
-510.5
|
-168.6
|
-182.2
|
-293.9
|
58.01
|
-130.8
|
-178.4
|
-138.8
|
-114.2
|
-110.9
|
239.1
|
Net margin
|
-180.29%
|
-380.87%
|
28.89%
|
-274.57%
|
-22.95%
|
-50.99%
|
-363.07%
|
13.67%
|
-69.94%
|
-61.23%
|
-136.78%
|
-148.99%
|
-143.26%
|
38.77%
|
EPS
2 |
-4.310
|
-11.18
|
2.560
|
-6.530
|
-2.150
|
-2.280
|
-3.410
|
0.5800
|
-1.260
|
-1.440
|
-1.064
|
-0.8480
|
-0.7700
|
1.656
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/28/22
|
5/9/22
|
8/8/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/9/23
|
2/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
242
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
243
|
1,061
|
1,112
|
400
|
510
|
482
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-138
|
-97.2
|
265
|
-505
|
-768
|
-68.5
|
-298
|
368
|
ROE (net income / shareholders' equity)
|
-
|
-190%
|
-1,266%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-74.4%
|
-47.7%
|
-83.8%
|
-27.2%
|
-26.9%
|
-11.9%
|
-19%
|
-
|
Assets
1 |
178.3
|
877.7
|
2,080
|
2,418
|
2,028
|
940.2
|
478.4
|
-
|
Book Value Per Share
2 |
-5.750
|
8.840
|
-4.640
|
-7.440
|
-5.140
|
-5.260
|
-4.340
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-5.320
|
-7.090
|
-2.320
|
-0.3700
|
-
|
Capex
1 |
1.86
|
220
|
57.5
|
89.1
|
53.8
|
18.1
|
8
|
9.2
|
Capex / Sales
|
9.95%
|
46.29%
|
5.01%
|
4.49%
|
5.47%
|
2.14%
|
0.81%
|
0.95%
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
4.09
USD Average target price
15.4
USD Spread / Average Target +276.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.79% | 572M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|